- Home
- ARQT vs XXI Comparison
ARQT vs XXI Comparison
Compare ARQT & XXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARQT | XXI |
|---|---|---|
| Founded | 2016 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.6B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ARQT | XXI |
|---|---|---|
| Price | $26.62 | $5.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 1.6M |
| Earning Date | 05-06-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $376,072,000.00 | N/A |
| Revenue This Year | $34.85 | N/A |
| Revenue Next Year | $29.39 | N/A |
| P/E Ratio | $824.50 | ★ N/A |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $16.68 | $4.15 |
| 52 Week High | $31.77 | $11.49 |
Technical Indicators
Market Signals| Indicator | ARQT | XXI |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 47.61 |
| Support Level | $24.91 | $4.93 |
| Resistance Level | $25.21 | $5.71 |
| Average True Range (ATR) | 1.03 | 0.30 |
| MACD | 0.22 | -0.10 |
| Stochastic Oscillator | 59.88 | 22.41 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.